Swiss National Bank Acquires 28,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Swiss National Bank lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 19.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 172,800 shares of the company’s stock after buying an additional 28,100 shares during the period. Swiss National Bank’s holdings in CRISPR Therapeutics were worth $10,501,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Allworth Financial LP raised its position in shares of CRISPR Therapeutics by 21.0% in the 2nd quarter. Allworth Financial LP now owns 737 shares of the company’s stock worth $45,000 after acquiring an additional 128 shares in the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of CRISPR Therapeutics by 8.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,944 shares of the company’s stock worth $118,000 after acquiring an additional 148 shares in the last quarter. HC Advisors LLC raised its position in shares of CRISPR Therapeutics by 2.1% in the 2nd quarter. HC Advisors LLC now owns 7,432 shares of the company’s stock worth $452,000 after acquiring an additional 154 shares in the last quarter. Bouvel Investment Partners LLC raised its position in shares of CRISPR Therapeutics by 1.2% in the 2nd quarter. Bouvel Investment Partners LLC now owns 18,536 shares of the company’s stock worth $1,126,000 after acquiring an additional 226 shares in the last quarter. Finally, National Asset Management Inc. raised its position in shares of CRISPR Therapeutics by 3.9% in the 1st quarter. National Asset Management Inc. now owns 7,329 shares of the company’s stock worth $461,000 after acquiring an additional 275 shares in the last quarter. 70.56% of the stock is owned by institutional investors.

CRISPR Therapeutics Trading Up 0.2 %

CRISPR Therapeutics stock opened at $57.74 on Monday. CRISPR Therapeutics AG has a 12 month low of $42.51 and a 12 month high of $86.95. The business’s 50 day simple moving average is $59.55 and its 200 day simple moving average is $64.42. The company has a market cap of $4.52 billion, a price-to-earnings ratio of -6.56 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported ($2.24) EPS for the quarter, beating the consensus estimate of ($2.30) by $0.06. CRISPR Therapeutics had a negative return on equity of 31.34% and a negative net margin of 4,831.79%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $3.53 million. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -9.23 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $64.61, for a total transaction of $1,615,250.00. Following the sale, the chief executive officer now owns 290,279 shares of the company’s stock, valued at approximately $18,754,926.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 75,000 shares of company stock worth $4,656,500. Insiders own 5.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. TheStreet lowered CRISPR Therapeutics from a “c” rating to a “d” rating in a research report on Thursday, August 18th. SVB Leerink boosted their target price on CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a research report on Monday, November 7th. Chardan Capital decreased their target price on CRISPR Therapeutics from $164.00 to $154.00 and set a “buy” rating for the company in a research report on Tuesday, August 9th. Citigroup lifted their price target on CRISPR Therapeutics from $53.00 to $83.00 and gave the company a “neutral” rating in a research note on Tuesday, August 2nd. Finally, Credit Suisse Group cut their price target on CRISPR Therapeutics from $90.00 to $78.00 in a research note on Wednesday, November 2nd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $102.69.

CRISPR Therapeutics Company Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.